{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:03:50Z","timestamp":1790413430505,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Sunitinib (SUN)-induced hypoxia within the tumor could promote the activation of the prodrug evofosfamide (EVO), locally releasing the cytotoxic DNA alkylator bromo-isophosphoramide mustard. SUNEVO, a phase II, open-label, single-arm trial, investigated the potential synergy of SUN plus EVO in advanced progressive pancreatic neuroendocrine tumors (panNETs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Systemic treatment-na\u00efve patients with advanced or metastatic, unresectable, grade 1\/2 panNETs with a Ki67\u00a0\u226420%, received EVO 340 mg\/m2 on days 8, 15, and 22 every 4\u2009weeks and sunitinib 37.5 mg\/day continuously. The primary endpoint was objective response rate, measured every 8\u2009weeks by RECIST version 1.1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From 2015 to 2018, 17 patients were enrolled. The median age was 62.4\u2009years, 47% had a Ki67\u00a0&amp;gt;10%, and 70.6% had liver metastasis. Patients received a median of five and four cycles of SUN and EVO, respectively. After a median follow-up of 15.7 months, 17.6% of patients achieved a complete (n\u00a0=\u20091) or partial response (n\u00a0=\u20092), and 11 patients had stable disease (64.7%). The median progression-free survival was 10.4 months (95% confidence interval, 2.6\u201318.0). Treatment-related adverse events (grade\u00a0\u22653) were observed in 64.7% of the patients, the most frequent being neutropenia (35.3%), fatigue (17.6%), and thrombopenia (11.8%). Treatment discontinuation due to toxicity was reported in 88.2% of the patients. No correlation was found between treatment response and DAXX, ATRX, MEN1, SETD2, and PTEN gene mutations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>SUN plus EVO had a negative toxicity profile that should be taken into account for further clinical research in advanced panNETs. The combination showed moderate activity in terms of treatment response that did not correlate with somatic mutations. (Clinical trial identification number: NCT02402062)<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Addition of hypoxia-activated prodrugs has been proposed as a potential mechanism to overcome tumor resistance to antiangiogenic agents. Sunitinib and evofosfamide, which were widely proposed as a potential synergistic option, showed modest efficacy in pancreatic neuroendocrine tumors (panNETs), reaching a median objective response rate of 17.6% and median progression-free survival of 10.4 months. Treatment response does not correlate with the biomarkers analyzed. The high systemic toxicity, with 88.2% of patients discontinuing the treatment, makes this therapeutic approach unfeasible and encourages future research to overcome panNETs' resistance to antiangiogenic agents with other therapies with a safer profile.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13885","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T07:19:45Z","timestamp":1625123985000},"page":"941-949","source":"Crossref","is-referenced-by-count":23,"title":["Sunitinib and Evofosfamide (<scp>TH<\/scp>-302) in Systemic Treatment-Na\u00efve Patients with Grade 1\/2 Metastatic Pancreatic Neuroendocrine Tumors: The <scp>GETNE<\/scp>-1408 Trial"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0134-4732","authenticated-orcid":false,"given":"Enrique","family":"Grande","sequence":"first","affiliation":[{"name":"Medical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rodriguez-Antona","sequence":"additional","affiliation":[{"name":"Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER), Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Medical Oncology, Hospital Universitario Marqu\u00e9s de Valdecilla, Instituto de investigaci\u00f3n sanitaria Valdecilla (IDIVAL), Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Alonso-Gordoa","sequence":"additional","affiliation":[{"name":"Medical Oncology, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Benavent","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Virgen del Roc\u00edo\/Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Vall Hebron University Hospital, Vall Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Teul\u00e9","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d'Oncologia (ICO)\u2013Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), L'Hospitalet del Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Custodio","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Sevilla","sequence":"additional","affiliation":[{"name":"Investigaci\u00f3n Cl\u00ednica y Traslacional en C\u00e1ncer\/Instituto de Investigaciones Biom\u00e9dicas de M\u00e1laga (IBIMA)\/Hospitales Universitarios Regional y Virgen de la Victoria, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hernando","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Vall Hebron University Hospital, Vall Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Gajate","sequence":"additional","affiliation":[{"name":"Medical Oncology, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Molina-Cerrillo","sequence":"additional","affiliation":[{"name":"Medical Oncology, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"D\u00edez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigaci\u00f3n Sanitaria Puerta de Hierro Segovia de Arana, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Santos","sequence":"additional","affiliation":[{"name":"Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Lanillos","sequence":"additional","affiliation":[{"name":"Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Garc\u00eda-Carbonero","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n 12 de Octubre (i+12), Universidad Complutense de Madrid (UCM), Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"2022011714460043100_onco13885-bib-0001","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/CCO.0b013e328353d7ba","article-title":"Neuroendocrine tumors of the digestive tract: Impact of new classifications and new agents on therapeutic approaches","volume":"4","author":"\u00d6berg","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"2022011714460043100_onco13885-bib-0002","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"2022011714460043100_onco13885-bib-0003","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"2022011714460043100_onco13885-bib-0004","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12032-014-0251-x","article-title":"A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients","volume":"12","author":"Yao","year":"2014","journal-title":"Med Oncol"},{"key":"2022011714460043100_onco13885-bib-0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000443168","article-title":"ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms","volume":"103","author":"Fave","year":"2016","journal-title":"Neuroendocrinology"},{"key":"2022011714460043100_onco13885-bib-0006","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2022011714460043100_onco13885-bib-0007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40487-015-0007-6","article-title":"An overview on the sequential treatment of pancreatic neuroendocrine tumors (panNETs)","volume":"3","author":"Alonso-Gordoa","year":"2015","journal-title":"Rare Cancers Ther"},{"key":"2022011714460043100_onco13885-bib-0008","doi-asserted-by":"crossref","first-page":"368","DOI":"10.15252\/emmm.201404271","article-title":"Metabolic and hypoxic adaptation to anti-angiogenic therapy: A target for induced essentiality","volume":"7","author":"McIntyre","year":"2015","journal-title":"EMBO Mol Med"},{"key":"2022011714460043100_onco13885-bib-0009","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2022011714460043100_onco13885-bib-0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00280-015-2920-7","article-title":"Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs","volume":"77","author":"Phillips","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022011714460043100_onco13885-bib-0011","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1080\/15384047.2014.1003005","article-title":"Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer","volume":"16","author":"Sun","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"2022011714460043100_onco13885-bib-0012","article-title":"Hypoxia-activated prodrug evofosfamide treatment in pancreatic ductal adenocarcinoma xenografts alters the tumor redox status to potentiate radiotherapy","author":"Kishimoto","year":"2020","journal-title":"Antioxid Redox Signal"},{"key":"2022011714460043100_onco13885-bib-0013","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.tranon.2017.06.010","article-title":"A combination of radiation and the hypoxia-activated prodrug evofosfamide (TH-302) is efficacious against a human orthotopic pancreatic tumor model","volume":"10","author":"Hajj","year":"2017","journal-title":"Transl Oncol"},{"issue":"suppl 15","key":"2022011714460043100_onco13885-bib-0014","doi-asserted-by":"crossref","first-page":"e15557a","DOI":"10.1200\/jco.2013.31.15_suppl.e15557","article-title":"Phase I study of TH-302, investigational hypoxia-targeted drug, in combination with sunitinib","volume":"31","author":"Starodub","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022011714460043100_onco13885-bib-0015","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00280-017-3256-2","article-title":"Phase I study of pazopanib plus TH-302 in advanced solid tumors","volume":"79","author":"Riedel","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022011714460043100_onco13885-bib-0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"key":"2022011714460043100_onco13885-bib-0017","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"2022011714460043100_onco13885-bib-0018","first-page":"1872","article-title":"Advances in pancreatic neuroendocrine tumor treatment","volume":"364","author":"Castellano","year":"2011","journal-title":"N Engl J Med"},{"key":"2022011714460043100_onco13885-bib-0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11523-020-00784-0","article-title":"Updated efficacy and safety outcomes for patients with well-differentiated pancreatic neuroendocrine tumors treated with sunitinib","volume":"16","author":"Fazio","year":"2021","journal-title":"Target Oncol"},{"key":"2022011714460043100_onco13885-bib-0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdw561","article-title":"Sunitinib in pancreatic neuroendocrine tumors: Updated progression-free survival and final overall survival from a phase III randomized study","volume":"28","author":"Faivre","year":"2017","journal-title":"Ann Oncol"},{"key":"2022011714460043100_onco13885-bib-0021","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jjco\/hyz009","article-title":"Efficacy and safety of sunitinib in Japanese patients with progressive, advanced\/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: Final analyses from a phase II study","volume":"49","author":"Ito","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"2022011714460043100_onco13885-bib-0022","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s11523-016-0462-5","article-title":"Patient-reported outcomes and quality of life with sunitinib versus placebo for pancreatic neuroendocrine tumors: Results from an international phase III trial","volume":"11","author":"Vinik","year":"2016","journal-title":"Target Oncol"},{"key":"2022011714460043100_onco13885-bib-0023","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noy015","article-title":"Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: A phase I surgical study","volume":"20","author":"Brenner","year":"2018","journal-title":"Neuro Oncol"},{"key":"2022011714460043100_onco13885-bib-0024","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/1078-0432.CCR-16-1113","article-title":"Alternative lengthening of telomeres and loss of DAXX\/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors","volume":"23","author":"Singhi","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13885","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13885","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/11\/941\/42203917\/oncolo_26_11_941.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/11\/941\/42203917\/oncolo_26_11_941.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T14:47:01Z","timestamp":1642430821000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/11\/941\/6508763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,7,14]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13885","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,7,14]]}}}